Eli Lilly's Retatrutide shows significant weight loss in key obesity trial.
Eli Lilly's Retatrutide showed significant weight loss in a key Phase 3 obesity trial.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
See this on the live map
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
Hubs
Briefings
More story pages
Gaza records over 125,000 skin infections in 2026, UNRWA reports, as rats and parasites surge in displacement camps.
UNRWA reported over 125,000 skin infections in Gaza from January to May 2026 due to rats, parasites, and poor living conditions. Medical teams are treating around 400 cases daily but face critical shortages of medicine.
Gonorrhoea & syphilis hit record levels in Europe
STD rates soar in Europe, new data reveals
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.